Deutsche Bank AG Grows Holdings in Sanara MedTech Inc. (NASDAQ:SMTI)

Deutsche Bank AG increased its position in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 75.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,547 shares of the company’s stock after buying an additional 1,525 shares during the period. Deutsche Bank AG’s holdings in Sanara MedTech were worth $118,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Citadel Advisors LLC increased its holdings in Sanara MedTech by 7.3% during the 4th quarter. Citadel Advisors LLC now owns 21,984 shares of the company’s stock worth $730,000 after purchasing an additional 1,491 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Sanara MedTech by 38.7% in the fourth quarter. Bank of America Corp DE now owns 3,778 shares of the company’s stock worth $125,000 after buying an additional 1,055 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Sanara MedTech in the fourth quarter worth $106,000. Northern Trust Corp increased its stake in shares of Sanara MedTech by 0.9% in the fourth quarter. Northern Trust Corp now owns 40,816 shares of the company’s stock worth $1,355,000 after buying an additional 358 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Sanara MedTech in the 4th quarter worth about $208,000. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Trading Up 0.3%

NASDAQ:SMTI opened at $29.17 on Wednesday. The firm has a market capitalization of $259.26 million, a P/E ratio of -29.46 and a beta of 1.38. The business has a 50 day simple moving average of $30.43 and a 200 day simple moving average of $33.07. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. Sanara MedTech Inc. has a 12-month low of $25.86 and a 12-month high of $39.08.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The company had revenue of $23.43 million for the quarter, compared to analyst estimates of $23.48 million. Equities research analysts predict that Sanara MedTech Inc. will post -1.1 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $46.00 price objective on shares of Sanara MedTech in a report on Wednesday, March 26th. HC Wainwright boosted their price target on Sanara MedTech from $51.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, May 15th.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.